Mark Froimson Net Worth

The estimated Net Worth of Mark Froimson is at least $726 Тысяча dollars as of 12 August 2024. Mark Froimson owns over 1,400 units of Pacira BioSciences Inc stock worth over $188,149 and over the last 7 years he sold PCRX stock worth over $112,409. In addition, he makes $424,946 as Independent Director at Pacira BioSciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Froimson PCRX stock SEC Form 4 insiders trading

Mark has made over 4 trades of the Pacira BioSciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 1,400 units of PCRX stock worth $16,212 on 12 August 2024.

The largest trade he's ever made was buying 1,400 units of Pacira BioSciences Inc stock on 12 August 2024 worth over $16,212. On average, Mark trades about 231 units every 183 days since 2017. As of 12 August 2024 he still owns at least 14,473 units of Pacira BioSciences Inc stock.

You can see the complete history of Mark Froimson stock trades at the bottom of the page.

Mark Froimson biography

Dr. Mark I. Froimson M.D. serves as Independent Director of the Company. Dr. Froimson is currently a Principal at Riverside Health Advisors, a consulting company that provides strategic advice and services to health care executive leaders. Dr. Froimson served as the President of the American Association of Hip and Knee Surgeons from March 2017 to March 2018. Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. Prior to his executive leadership position at Trinity Health, Dr. Froimson was President and Chief Executive Officer of Euclid Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held a variety of leadership positions, including President of the professional staff, Vice Chair of the Orthopedic and Rheumatologic Institute, and member of the board of governors and board of trustees. Dr. Froimson received a B.S. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine and an MBA from the Weatherhead School of Business at Case Western Reserve University.

What is the salary of Mark Froimson?

As the Independent Director of Pacira BioSciences Inc, the total compensation of Mark Froimson at Pacira BioSciences Inc is $424,946. There are 17 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.

How old is Mark Froimson?

Mark Froimson is 59, he's been the Independent Director of Pacira BioSciences Inc since 2018. There are 9 older and 12 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.

What's Mark Froimson's mailing address?

Mark's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.

Insiders trading at Pacira BioSciences Inc

Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon и Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.

What does Pacira BioSciences Inc do?

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

Complete history of Mark Froimson stock trades at Pacira BioSciences Inc

Pacira BioSciences Inc executives and stock owners

Pacira BioSciences Inc executives and other stock owners filed with the SEC include:

• David Stack,
  Chairman of the Board, Chief Executive Officer
• Max Reinhardt,
  President
• Dennis McLoughlin,
  Chief Commercial Officer
• Kristen Williams,
  Chief Administrative Officer, Secretary
• Roy Winston,
  Chief Clinical Officer
• David M. Stack,
  Chairman & CEO
• Charles Reinhart,
  Chief Financial Officer
• Dr. Roy Winston M.D.,
  Chief Medical Officer
• Christopher Christie,
  Director
• Max Reinhardt,
  Pres of Rest of World
• Dr. Jonathan Slonin M.D.,
  Chief Clinical Officer
• Kristen Williams,
  Chief Admin. Officer & Sec.
• Charles A. Reinhart III, CPA, M.B.A.,
  Chief Financial Officer
• Paul Hastings,
  Lead Independent Director
• Laura Brege,
  Independent Director
• John Longenecker,
  Independent Director
• Mark Kronenfeld,
  Independent Director
• Yvonne Greenstreet,
  Independent Director
• Mark Froimson,
  Independent Director
• Gary Pace,
  Independent Director
• Susan Mesco,
  IR Contact Officer
• Andreas Wicki,
  Independent Director
• Charles Laranjeira,
  Chief Technical Officer
• Kristen Williams J.D.,
  Chief Admin. Officer & Sec.
• Daryl Gaugler,
  Chief Operating Officer
• Robert J. Weiland,
  Sr. VP of Alliance Management
• Richard Kahr,
  VP of HR
• Charles Laranjeira,
  Chief Technical Officer
• Lauren Bullaro Riker,
  Principal Accounting Officer & VP of Fin.
• Dennis L Winger,
  Director
• Scott Braunstein,
  SVP, Strategy & Corp. Dev.
• Robert J. Weiland,
  Chief Commercial Officer
• Richard Scranton,
  Chief Scientific Officer
• James B Jones,
  SVP & Chief Medical Officer
• James S Scibetta,
  Chief Financial Officer
• Gary Patou,
  Director
• Taunia Markvicka,
  Vice President, Commercial
• Advisors Llc Orbi Med Capit...,
  
• Venture Partners Vi Lp Sand...,
  
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Carl L Gordon,
  Director
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Venture Partners Vi Lp Sand...,
  
• Luke Evnin,
  Director
• John Pratt,
  General Manager, San Diego
• Vaughn Mgadicke Ansbert Kai...,
  
• Bioventures Cayman Ltd Hbm,
  10% owner
• Fred A Middleton,
  Director
• Venture Partners Vi Lp Sand...,
  
• Venture Partners Vi Lp Sand...,
  
• Abraham Ceesay,
  Director
• Alethia Young,
  Director
• Marcelo Bigal,
  Director
• Michael J. Yang,
  Director
• Donald C. Manning,
  Chief Medical Officer
• Lauren Riker,
  Senior Vice President, Finance
• Anthony Molloy,
  Chief Lgl & Compliance Officer
• Daryl Gaugler,
  Chief Operating Officer
• Ronald J. Jr. Ellis,
  Chief Strategy Officer
• Jonathan Slonin,
  Chief Medical Officer
• Frank D. Lee,
  Chief Executive Officer